TXN and neoplasm: The management of mitochondrial ROS levels is a key feature of acute myeloid leukemia, where the protein kinase-ε activation controls the content of mROS by impacting on some ROS-buffering enzymes, such as thioredoxin and glutathione synthetase, thereby promoting the tumor progression in vivo (32).